These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 23800379

  • 1. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
    Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L, Kowal K.
    Arthritis Res Ther; 2013; 15(3):R69. PubMed ID: 23800379
    [Abstract] [Full Text] [Related]

  • 2. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure.
    Ptaszynska-Kopczynska K, Marcinkiewicz-Siemion M, Lisowska A, Waszkiewicz E, Witkowski M, Jasiewicz M, Miklasz P, Jakim P, Galar B, Musial WJ, Kaminski KA.
    Cytokine; 2016 Apr; 80():7-12. PubMed ID: 26916171
    [Abstract] [Full Text] [Related]

  • 3. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
    Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O.
    Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
    [Abstract] [Full Text] [Related]

  • 4. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
    Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, Egido J, Blanco-Colio LM.
    Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
    [Abstract] [Full Text] [Related]

  • 5. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study.
    Llauradó G, González-Clemente JM, Maymó-Masip E, Subías D, Vendrell J, Chacón MR.
    PLoS One; 2012 Dec; 7(8):e43919. PubMed ID: 22937125
    [Abstract] [Full Text] [Related]

  • 6. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension.
    Jasiewicz M, Kowal K, Kowal-Bielecka O, Knapp M, Skiepko R, Bodzenta-Lukaszyk A, Sobkowicz B, Musial WJ, Kaminski KA.
    Cytokine; 2014 Mar; 66(1):40-5. PubMed ID: 24548423
    [Abstract] [Full Text] [Related]

  • 7. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.
    Rusu CC, Racasan S, Kacso IM, Ghervan L, Moldovan D, Potra A, Patiu IM, Bondor C, Caprioara MG.
    Int Urol Nephrol; 2015 Dec; 47(12):2023-30. PubMed ID: 26433887
    [Abstract] [Full Text] [Related]

  • 8. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis.
    Bielecki M, Kowal K, Lapinska A, Chyczewski L, Kowal-Bielecka O.
    Adv Med Sci; 2013 Dec; 58(1):126-33. PubMed ID: 23640944
    [Abstract] [Full Text] [Related]

  • 9. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.
    Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, García Morillo JS, Egido J, Noval ML, Ferrando-Martinez S, Blanco-Colio LM, Genebat M, Villar JR, Moreno-Luna R, Moreno JA.
    PLoS One; 2014 Dec; 9(3):e90541. PubMed ID: 24594990
    [Abstract] [Full Text] [Related]

  • 10. Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study.
    Rojo-Martínez G, Maymó-Masip E, Rodríguez MM, Solano E, Goday A, Soriguer F, Valdés S, Chaves FJ, Delgado E, Colomo N, Hernández P, Vendrell J, Chacón MR.
    PLoS One; 2014 Dec; 9(6):e101250. PubMed ID: 24978196
    [Abstract] [Full Text] [Related]

  • 11. Role of the tumour necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in autoimmune thyroid disease.
    Peng S, Yu X, Zhao X, Wang X, Sun X, Han C, Shan Z, Li C, Teng W.
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):783-790. PubMed ID: 28636775
    [Abstract] [Full Text] [Related]

  • 12. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
    Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, Fernández E, Blanco-Colio LM.
    J Nephrol; 2013 Dec; 26(6):1105-13. PubMed ID: 23475462
    [Abstract] [Full Text] [Related]

  • 13. Increased serum levels of soluble CD163 in patients with scleroderma.
    Shimizu K, Ogawa F, Yoshizaki A, Akiyama Y, Kuwatsuka Y, Okazaki S, Tomita H, Takenaka M, Sato S.
    Clin Rheumatol; 2012 Jul; 31(7):1059-64. PubMed ID: 22453843
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum levels of soluble CD163 in patients with systemic sclerosis.
    Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, Fukushima S, Inoue Y, Ihn H.
    Rheumatol Int; 2012 Feb; 32(2):403-7. PubMed ID: 21120485
    [Abstract] [Full Text] [Related]

  • 16. Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer.
    Avilés-Jurado FX, Terra X, Gómez D, Flores JC, Raventós A, Maymó-Masip E, León X, Serrano-Gonzalvo V, Vendrell J, Figuerola E, Chacón MR.
    Eur Arch Otorhinolaryngol; 2015 Jul; 272(7):1733-41. PubMed ID: 24858806
    [Abstract] [Full Text] [Related]

  • 17. Soluble CD163 and TWEAK in early pregnancy gestational diabetes and later glucose intolerance.
    Dereke J, Nilsson J, Nilsson C, Strevens H, Landin-Olsson M, Hillman M.
    PLoS One; 2019 Jul; 14(5):e0216728. PubMed ID: 31071174
    [Abstract] [Full Text] [Related]

  • 18. Serum changes in sTWEAK and its scavenger receptor sCD163 in ultramarathon athletes running the 24-h race.
    Benedetti S, Gemma Nasoni M, Palma F, Citarella R, Luchetti F.
    Cytokine; 2021 Jan; 137():155315. PubMed ID: 33011401
    [Abstract] [Full Text] [Related]

  • 19. Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study.
    Díaz-López A, Chacón MR, Bulló M, Maymó-Masip E, Martínez-González MA, Estruch R, Vendrell J, Basora J, Díez-Espino J, Covas MI, Salas-Salvadó J.
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3482-90. PubMed ID: 23760626
    [Abstract] [Full Text] [Related]

  • 20. Soluble CD163 as a Potential Biomarker in Systemic Sclerosis.
    Frantz C, Pezet S, Avouac J, Allanore Y.
    Dis Markers; 2018 Aug; 2018():8509583. PubMed ID: 29805720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.